Back to search

Article

Prediction of binding of FDA approved drug Ledipasvir to SARS-CoV2 mutants: an in silico study

2021-09-07

Abstract excerpt

The surge of variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is a global concern to public health as the mutations in the genome may alter the virulence of the virus, which poses a challenge to manage the disease. The virus depends on RNA dependent RNA polymerases [RdRp(s)] and its associated non-structural proteins for replication. Therefore, RdRp is a target of antiviral drugs. Several mu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f4d6a945-8f5e-5c02-a8e3-1ac9c746b3e2
DOI
10.21203/rs.3.rs-882289/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Prediction of binding of FDA approved drug Ledipasvir to SARS-CoV2 mutants: an in silico studyDOI 10.21203/rs.3.rs-882289/v1
Select a neighboring publication to make it the new centre.